Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs Conventional Treatment in Valvular AF (DECISIVE)
NCT02982850Phase 4Completed
- Sponsor
- Asan Medical Center
- Start
- Dec 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Composite of clinical cerebral infarct or new cerebral MRI lesions at 12 months. Started Dec 2016; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02982850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982850.